Literature DB >> 25756506

Are there alternative ways to quantify the real benefit of novel agents in oncology? - the 'death pace'.

Vincenzo Formica, Eugenio Montefusco, Mario Roselli.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25756506      PMCID： PMC4622992          DOI： 10.1080/15384047.2014.1002368

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


× No keyword cloud information.
  2 in total

1.  Potential novel role of bevacizumab in glioblastoma and cervical cancer.

Authors:  Andrew K L Goey; William D Figg
Journal:  Cancer Biol Ther       Date:  2014-07-21       Impact factor: 4.742

2.  Improved survival with bevacizumab in advanced cervical cancer.

Authors:  Krishnansu S Tewari; Michael W Sill; Harry J Long; Richard T Penson; Helen Huang; Lois M Ramondetta; Lisa M Landrum; Ana Oaknin; Thomas J Reid; Mario M Leitao; Helen E Michael; Bradley J Monk
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245
  2 in total
  1 in total

1.  Predictive factors for 6 vs 12 cycles of Folfiri-Bevacizumab in metastatic colorectal cancer.

Authors:  Vincenzo Formica; Maria Teresa Ionta; Bruno Massidda; Giacomo Vessia; Luigi Maiorino; Rossana Casaretti; Donato Natale; Giuseppe Barberis; Gianfranco Filippelli; Ettore Greco; Livio Blasi; Sergio Mancarella; Anna Russo; Enrico Barbato; Liberato Di Lullo; Mario Roselli
Journal:  Oncotarget       Date:  2017-12-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.